Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00001068 |
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Lamivudine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-Up Study to ACTG 175 |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
PER AMENDMENT 8/27/96:
Study ID Numbers: | ACTG 303 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00001068 |
Health Authority: | United States: Federal Government |
Zalcitabine Didanosine Drug Therapy, Combination AIDS-Related Complex |
Antiviral Agents Zidovudine Lamivudine |
Sexually Transmitted Diseases, Viral Acquired Immunodeficiency Syndrome Zalcitabine Disease Progression Zidovudine Lamivudine AIDS-Related Complex |
Immunologic Deficiency Syndromes Virus Diseases Didanosine HIV Infections Sexually Transmitted Diseases Retroviridae Infections |
Anti-Infective Agents RNA Virus Infections Disease Attributes Anti-HIV Agents Slow Virus Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Infection |
Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Pathologic Processes Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections Nucleic Acid Synthesis Inhibitors |